PRKDC and acute myeloid leukemia: Combination of the selective DNA-PK inhibitor with Mylotarg in two AML xenograft models is well-tolerated, provides significant efficacy and survival benefit compared to Mylotarg alone and could offer a new combination approach to AML therapy.